FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210261819> ?p ?o ?g. }

• W4210261819 endingPage "173" @default.
• W4210261819 startingPage "173" @default.
• W4210261819 abstract "There are more single inhaler device triple therapy available for COPD patients now. However, the effect of long-term triple therapy fixed dose combination (FDC) on mortality remains unclear. This study aimed to evaluate the impact of one-year single inhaler device triple therapy, including long-acting β2-agonists (LABAs), long-acting muscarinic receptor antagonists (LAMAs), and inhaled corticosteroids (ICSs), with dual therapies, comprised of either LABA/LAMA or ICS/LABA, on the mortality of patients with COPD. We searched the PubMed, Cochrane library, Web of Science, Embase databases, and clinical trial registry of clinicaltrials.gov and WHO ICTRP. Randomized controlled trials (RCTs) compared single inhaler device triple and dual therapies for 52 weeks were selected for the meta-analysis. The primary endpoint was all-cause mortality. A total of 6 RCTs were selected for the meta-analysis, including 10,274 patients who received single inhaler device triple therapy (ICS/LABA/LAMA FDC) and 12,395 patients who received ICS/LABA or LABA/LAMA dual therapy. Risk of death was significantly lower in the ICS/LABA/LAMA FDC group compared to the LABA/LAMA group (RR = 0.69, 95% CI = 0.53-0.90, p = 0.007). There was no significant difference in mortality between the ICS/LABA/LAMA FDC and ICS/LABA therapy groups (RR = 0.94, 95% CI = 0.72-1.24, p = 0.66). In addition, patients receiving ICS/LABA/LAMA FDC therapy had less moderate or severe exacerbations compared with the dual therapy groups (RR = 0.76, 95% CI = 0.73-0.80, p < 0.001 for LABA/LAMA; RR = 0.84, 95% CI = 0.78-0.90, p < 0.001 for ICS/LABA). By contrast, the risk of pneumonia in the ICS/LABA/LAMA FDC group was higher than in the LABA/LAMA group (RR = 1.43, 95% CI = 1.21-1.68, p < 0.001). In conclusion, ICS/LABA/LAMA FDC therapy could help improve the clinical outcomes of patients with COPD. However, triple therapy could increase the risk of pneumonia in comparison with LABA/LAMA dual therapy." @default.
• W4210261819 created "2022-02-08" @default.
• W4210261819 creator A5006925381 @default.
• W4210261819 creator A5007543643 @default.
• W4210261819 creator A5016416517 @default.
• W4210261819 creator A5022398404 @default.
• W4210261819 creator A5023589804 @default.
• W4210261819 creator A5058477490 @default.
• W4210261819 creator A5087320814 @default.
• W4210261819 date "2022-01-25" @default.
• W4210261819 modified "2023-10-16" @default.
• W4210261819 title "The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" @default.
• W4210261819 cites W2045616259 @default.
• W4210261819 cites W2098923148 @default.
• W4210261819 cites W2161374186 @default.
• W4210261819 cites W2513086234 @default.
• W4210261819 cites W2582480512 @default.
• W4210261819 cites W2588681363 @default.
• W4210261819 cites W2604577460 @default.
• W4210261819 cites W2604743750 @default.
• W4210261819 cites W2737662840 @default.
• W4210261819 cites W2766594601 @default.
• W4210261819 cites W2785999277 @default.
• W4210261819 cites W2797560548 @default.
• W4210261819 cites W2802221596 @default.
• W4210261819 cites W2888143498 @default.
• W4210261819 cites W2893154769 @default.
• W4210261819 cites W2897953679 @default.
• W4210261819 cites W2899919480 @default.
• W4210261819 cites W2904462760 @default.
• W4210261819 cites W2910341328 @default.
• W4210261819 cites W2912675200 @default.
• W4210261819 cites W2913843126 @default.
• W4210261819 cites W2917301053 @default.
• W4210261819 cites W2955803684 @default.
• W4210261819 cites W2960162056 @default.
• W4210261819 cites W2989863696 @default.
• W4210261819 cites W2991383511 @default.
• W4210261819 cites W2993660735 @default.
• W4210261819 cites W2995635209 @default.
• W4210261819 cites W2996365559 @default.
• W4210261819 cites W3002196117 @default.
• W4210261819 cites W3011621519 @default.
• W4210261819 cites W3016201212 @default.
• W4210261819 cites W3033407864 @default.
• W4210261819 cites W3037411127 @default.
• W4210261819 cites W3041064922 @default.
• W4210261819 cites W3044255692 @default.
• W4210261819 cites W3044698871 @default.
• W4210261819 cites W3088113156 @default.
• W4210261819 cites W3097151741 @default.
• W4210261819 cites W3126194943 @default.
• W4210261819 cites W3176248074 @default.
• W4210261819 cites W3176486399 @default.
• W4210261819 cites W3182699010 @default.
• W4210261819 doi "https://doi.org/10.3390/life12020173" @default.
• W4210261819 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35207460" @default.
• W4210261819 hasPublicationYear "2022" @default.
• W4210261819 type Work @default.
• W4210261819 citedByCount "4" @default.
• W4210261819 countsByYear W42102618192022 @default.
• W4210261819 countsByYear W42102618192023 @default.
• W4210261819 crossrefType "journal-article" @default.
• W4210261819 hasAuthorship W4210261819A5006925381 @default.
• W4210261819 hasAuthorship W4210261819A5007543643 @default.
• W4210261819 hasAuthorship W4210261819A5016416517 @default.
• W4210261819 hasAuthorship W4210261819A5022398404 @default.
• W4210261819 hasAuthorship W4210261819A5023589804 @default.
• W4210261819 hasAuthorship W4210261819A5058477490 @default.
• W4210261819 hasAuthorship W4210261819A5087320814 @default.
• W4210261819 hasBestOaLocation W42102618191 @default.
• W4210261819 hasConcept C126322002 @default.
• W4210261819 hasConcept C168563851 @default.
• W4210261819 hasConcept C203092338 @default.
• W4210261819 hasConcept C2776042228 @default.
• W4210261819 hasConcept C2776478404 @default.
• W4210261819 hasConcept C2776780178 @default.
• W4210261819 hasConcept C2780261241 @default.
• W4210261819 hasConcept C2780911369 @default.
• W4210261819 hasConcept C71924100 @default.
• W4210261819 hasConcept C95190672 @default.
• W4210261819 hasConceptScore W4210261819C126322002 @default.
• W4210261819 hasConceptScore W4210261819C168563851 @default.
• W4210261819 hasConceptScore W4210261819C203092338 @default.
• W4210261819 hasConceptScore W4210261819C2776042228 @default.
• W4210261819 hasConceptScore W4210261819C2776478404 @default.
• W4210261819 hasConceptScore W4210261819C2776780178 @default.
• W4210261819 hasConceptScore W4210261819C2780261241 @default.
• W4210261819 hasConceptScore W4210261819C2780911369 @default.
• W4210261819 hasConceptScore W4210261819C71924100 @default.
• W4210261819 hasConceptScore W4210261819C95190672 @default.
• W4210261819 hasFunder F4320326159 @default.
• W4210261819 hasIssue "2" @default.
• W4210261819 hasLocation W42102618191 @default.
• W4210261819 hasLocation W42102618192 @default.
• W4210261819 hasLocation W42102618193 @default.
• W4210261819 hasLocation W42102618194 @default.
• W4210261819 hasOpenAccess W4210261819 @default.

• next